
Boehringer Ingelheim has said it plans to invest around €17 million in its biopharmaceutical development and manufacturing capabilities at Biberach, …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

